Table 5.
Comparison of secondary measures of clinical effectiveness between the matched treatment groups during the outcome year
| Outcome | EH (n=979) |
OH (n=979) |
P-valuea |
|---|---|---|---|
| Treatment stability (1) | |||
| Stable, n (%) | 515 (52.6%) | 595 (60.8%) | – |
| Adjusted ORb (95% CI) | 0.67 (0.48, 0.92) | 1.00 | |
| Treatment stability (2) | |||
| Stable, n (%) | 589 (60.2%) | 636 (65.0%) | |
| Adjusted ORc (95% CI) | 0.78 (0.57, 1.06) | 1.00 | |
| SABA usage (μg/day) | |||
| 0, n (%) | 143 (14.6%) | 134 (13.7%) | <0.001d |
| 1–100, n (%) | 128 (13.1%) | 102 (10.4%) | |
| 101–200, n (%) | 237 (24.2%) | 224 (22.9%) | |
| 201–400, n (%) | 260 (26.6%) | 268 (27.4%) | |
| 401–800, n (%) | 154 (15.7%) | 167 (17.1%) | |
| 801+, n (%) | 57 (5.8%) | 84 (8.6%) | |
| Adjusted ORe (95% CI) | 0.69 (0.59, 0.81) | 1.00 | |
| Controller–reliever ratio | |||
| <0.5, n (%) | 272 (27.8%) | 258 (26.4%) | 0.430 |
| ≥0.5, n (%) | 707 (72.2%) | 721 (73.6%) | |
| Mean (SD) | 0.6 (0.2) | 0.6 (0.2) | 0.590 |
| Median (IQR) | 0.6 (0.5, 0.8) | 0.6 (0.5, 0.8) | |
Notes:
Conditional logistic regression, except where noted;
adjusted for baseline rhinitis nasal spray and exacerbations (clinical);
adjusted for baseline rhinitis nasal spray and nonasthma-related consultations (categorized);
ordinal regression;
odds of EH patients being in a higher SABA category compared with OH patients, adjusted for baseline daily SABA dosage. Easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant (P<0.05).
Abbreviations: CI, confidence intervals; EH, Easyhaler®; IQR, interquartile range; OH, other inhalers; OR, odds ratio; SABA, short-acting β2 receptor agonist; SD, standard deviation.